U.S. patent application number 10/664331 was filed with the patent office on 2004-04-01 for methods for stable transduction of cells with viral vectors.
Invention is credited to Chang, Yung-Nien, Davis, Brian, Dropulic, Boro, Han, Wei, Humeau, Laurent, Lesher, Mechelle, Lu, Xiaobin, Slepushkin, Vladimir.
Application Number | 20040062756 10/664331 |
Document ID | / |
Family ID | 24619453 |
Filed Date | 2004-04-01 |
United States Patent
Application |
20040062756 |
Kind Code |
A1 |
Humeau, Laurent ; et
al. |
April 1, 2004 |
Methods for stable transduction of cells with viral vectors
Abstract
The present invention provides methods, as well as compositions
related thereto, for the efficient transduction of cells using
viral vectors. The efficiency of transduction is increased by
contacting the cell to be transduced with one or more molecules
that bind the cell surface. Contact with a cell surface binding
molecule may occur before, after, or simultaneously with contact
between the viral vector and the cell. The transduced vectors may
be constructed to express a gene of interest, permitting the
transduced cells to be used as therapeutic and prophylactic
agents.
Inventors: |
Humeau, Laurent;
(Germantown, MD) ; Han, Wei; (Montgomery Village,
MD) ; Lu, Xiaobin; (Germantown, MD) ;
Slepushkin, Vladimir; (Damascus, MD) ; Lesher,
Mechelle; (Columbia, MD) ; Davis, Brian;
(Gaithersburg, MD) ; Chang, Yung-Nien;
(Cockeysville, MD) ; Dropulic, Boro; (Ellicott
City, MD) |
Correspondence
Address: |
MORRISON & FOERSTER LLP
3811 VALLEY CENTRE DRIVE
SUITE 500
SAN DIEGO
CA
92130-2332
US
|
Family ID: |
24619453 |
Appl. No.: |
10/664331 |
Filed: |
September 16, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10664331 |
Sep 16, 2003 |
|
|
|
09653088 |
Aug 31, 2000 |
|
|
|
6627442 |
|
|
|
|
Current U.S.
Class: |
424/93.21 ;
435/456 |
Current CPC
Class: |
A61P 31/18 20180101;
A61P 35/00 20180101; C12N 2740/16043 20130101; C12N 15/86 20130101;
A61K 48/00 20130101; A61P 31/12 20180101 |
Class at
Publication: |
424/093.21 ;
435/456 |
International
Class: |
A61K 048/00; C12N
015/867 |
Claims
1. A method for stable transduction of primary cells of the
hematopoietic system and/or hematopoietic stem cells comprising
contacting the surface of said cells with both a lentiviral vector
and at least one molecule which binds said cell surface wherein
said contacting occurs in vitro or ex vivo and wherein greater than
about 90% of the cells are stably transduced after about 14
days.
2. The method of claim 1 wherein said contacting the cells with a
lentiviral vector occurs before contacting the cells with at least
one cell surface binding molecule.
3. The method of claim 1 wherein said contacting the cells with a
lentiviral vector occurs simultaneously with contacting the cells
with at least one cell surface binding molecule.
4. The method of claim 1 wherein said contacting the cells with a
lentiviral vector occurs after contacting the cells with at least
one cell surface binding molecule.
5. The method of claim 1 where said contacting with a lentiviral
vector occurs more than once.
6. The method of claim 1 wherein said lentiviral vector is derived
from HIV-1.
7. The method of claim 1 wherein said cell surface binding molecule
is an antibody, a ligand or a cell surface molecule.
8. The method of claim 1 wherein said lentiviral vector comprises
at least one cis-acting nucleotide sequence derived from the gag,
pol, env, vif, vpr, vpu, tat or rev genes.
9. The method of claim 8 wherein said sequence is not expressed or
is a fragment or a mutant of the gag, pol, env, vif, vpr, vpu, tat
or rev genes.
10. The method of claim 1 wherein said lentiviral vector is derived
from HIV-2.
11. The method of claim 1 wherein said lentiviral vector is a
pseudotyped vector.
12. The method of claim 11 wherein said pseudotyped vector contains
the vesicular stomatitis virus G envelope protein.
13. The method of claim 1 wherein said lentiviral vector is a
chimeric vector comprising HIV-1 and HIV-2 sequences.
14. The method of claim 1 wherein said hematopoietic cell is a CD4
positive cell.
15. The method of claim 1 wherein said hematopoietic cell is a
lymphocyte.
16. The method of claim 15 wherein said lymphocyte is a CD4 or CD8
positive cell.
17. The method of claim 1 wherein said hematopoietic cell is a CD34
positive cell.
18. The method of claim 17 wherein said at least one cell surface
binding molecule comprises a molecule selected from FLT-3 ligand,
TPO ligand, Kit ligand, or antibodies that are cell surface binding
analogs of FLT-3 ligand, TPO ligand, or Kit ligand.
19. The method of claim 1 wherein said at least one cell surface
binding molecule comprises a molecule selected from FLT-3 ligand,
TPO ligand, Kit ligand, or antibodies that are cell surface binding
analogs of FLT-3 ligand, TPO ligand, or Kit ligand.
20. The method of claim 1 wherein the said cell is a dendritic cell
or a cell capable of differentiating into a dendritic cell.
21. The method of claim 20 wherein said at least one cell surface
binding molecule is selected from compositions comprising GM-CSF,
IL-4, and TNF-alpha; GM-CSF and interferon-alpha; or antibodies
that are cell surface binding analogs of GM-CSF, IL-4, and
TNF-alpha; GM-CSF or interferon-alpha.
22. The method of claim 14 wherein said at least one cell surface
binding molecule is selected from the group consisting of CD3
antibodies and fragments thereof, CD28 antibodies and fragments
thereof, and combinations of said antibodies and fragments
thereof.
23. The method of claim 22 wherein said at least one cell surface
binding molecule comprises a combination of CD3 and CD28 antibodies
immobilized on coated beads.
24. The method of claim 3 further comprising culturing the cells
under conditions conducive to growth and/or proliferation.
25. The method of claim 24 wherein said conditions comprise further
incubation with a cell surface binding molecule or a cytokine.
26. The method of claim 25 wherein said cytokine is
interleukin-2.
27. The method of claim 24 wherein said culturing is for about
seven days.
28. The method of claim 24 wherein said culturing is for about 14
days.
29. The method of claim 3 wherein said contacting the cells with a
lentiviral vector is for about 24 hours and is optionally repeated
at least once.
30. The method of claim 1 wherein the lentiviral vector is present
at an MOI of less than 500.
31. A method to introduce genetic material into a living subject
comprising introduction of a cell transduced by the method of claim
1.
32. The method of claim 4 further comprising culturing the cells
under conditions conducive to growth and/or proliferation.
33. The method of claim 1 wherein said contacting occurs ex vivo.
Description
TECHNICAL FIELD
[0001] The present invention is directed to methods, as well as
compositions related thereto, for the efficient and stable
transduction of cells using viral vectors. The methods increase the
efficiency of transduction by contacting the cell to be transduced
with one or more molecules that bind the cell surface. The
contacting step may occur before, after, or simultaneously with,
introduction of the viral vector to the cells. The present
invention also concerns the use of the stably transduced cells in
other applications, including expression of nucleic acids borne by
the vector or therapy of living organisms.
BACKGROUND ART
[0002] "Transfection", which generally refers to techniques for the
introduction of genetic material into a cell, has contributed
greatly to the molecular and recombinant revolutions in biology.
Examples of transfection techniques for use with higher eukaryotic
cells include calcium phosphate precipitation, DEAE-dextran
treatment, electroporation, microinjection, lipofection, viral
infection, and other methods found in numerous scientific textbooks
and journals.
[0003] Among transfection techniques, the use of viral infection is
unique in that a virus' naturally occurring means of introducing
its genetic material into a cell is taken advantage of to transfer
a nucleic acid molecule of interest into a cell. Examples of
viruses modified and applied to such techniques include
adenoviruses, adeno-associated viruses, herpes simplex viruses, and
retroviruses. Generally, nucleic acid molecules of interest may be
cloned into a viral genome. Upon replication and packaging of the
viral genome, the resultant viral particle is capable of delivering
the nucleic acid of interest into a cell via the viral entry
mechanism.
[0004] Commonly, the viral genome is first made replication
deficient by nucleic acid manipulation before the addition of the
nucleic acid of interest. The resultant viral genome, or viral
vector, requires the use of a helper virus or a packaging system to
complete viral particle assembly and release from a cell. When a
viral vector or viral particle is used to transfer genetic material
of interest into a cell, the technique is referred to as
"transduction". Thus generally, to "transduce" a cell is to use a
viral vector or viral particle to transfer genetic material into a
cell.
[0005] Among transduction techniques, the use of retroviruses has
been the subject of great interest for the genetic modification of
mammalian cells. Of particular interest is the use of modified
retroviruses to introduce genetic material into cells to treat
genetic defects and other diseases. An example of this approach is
seen in the case of cells of the hematopoietic system, where
retroviruses and lentiviral vectors are the subject of intense
research.
[0006] Movassagh et al., for example, discuss their studies on
their attempts to increase the efficiency of retrovirus mediated
transduction by including results from studies on the cell cycle of
activated T cells. As such, their results are dependent upon active
cell division during transduction. The work is also limited to the
use of a murine onco-retrovirus and the requirement for significant
prestimulation of the cells before transduction.
[0007] June et al. (WO 96/34970) describe the use of T cell
stimulation as a means to increase T cell transfection. Other work
on T cell transduction with activated or stimulated cells include
those of Douglas et al., Hooijberg et al, Onodera et al., Klebba et
al., Barry et al., and Unutmaz et al. Unfortunately, none of this
work demonstrated transduction efficiencies of greater than about
65%.
[0008] Costello et al. describe the transduction of both stimulated
and non-stimulated T cells using Human Immunodeficiency Virus-1
(HIV-1) lentiviral vectors. They observed only about a maximum of
17% efficiency with stimulated primary T cells and less than 19%
efficiency with non-stimulated T cells. They also noted a limited
ability to increase efficiency to no more than 36% in stimulated T
cells by including the presence of HIV-1 accessory proteins.
[0009] Chinnasamy et al. also describe an increase in the
efficiency of transduction in the presence of HIV-1 accessory
proteins in both non-stimulated and mitogen stimulated T cells.
Like Movassagh et al, Chinnasamy et al. prestimulated blood
lymphocytes for significant periods prior to transduction with a
lentiviral vector. While Chinnasamy et al. initially observed a
greater than 96% transduction efficiency three days after
transduction, the percentage of stably transduced cells decreased
to 71.2% two weeks after transduction. Haas et al. also observed
transient transduction and "pseudotransduction" in cells transduced
with a lentiviral vector capable of expressing a marker gene (green
fluorescent protein). Even three days post transduction,
significant (over 10%) transient transduction was detected based on
non-integrative expression of the marker gene in transduced primary
CD34+ cord blood cells. Such expression from transient transduction
remained detectable at about 5% even seven days post-transduction.
Only after about 10 days post transduction did expression from
transient transduction mirror that in cells transduced with a
markerless vector.
[0010] Therefore, Chinnasamy et al were not able to achieve stable
transduction, where an integrated form of the viral vector has been
inserted into the chromosomal DNA of the transduced cell, of
primary lymphocytes beyond 71.2% as reflected by the efficiency
after two weeks. This was despite the use of cytokines to
prestimulated the cells. Furthermore, Chinnasamy describe their
inability to significantly transduce (only 3.6% 14 days post
transduction) non-stimulated lymphocytes with a HIV vector that did
not express accessory proteins (Vif, Vpr, Vpu and Nef), even though
the cells were later stimulated with the PHA mitogen and the IL-2
cytokine post-transduction. While the results were improved
somewhat with the use of non-stimulated cells and vectors
containing accessory proteins, in no case was the efficiency of
stable transduction of stimulated or non-stimulated cells greater
than 75% on day 14 post transduction, irrespective of the
stimulatory protocol used with the vector.
[0011] Low frequencies of stable transduction with lentiviral
vectors was also observed by Hass et al., who could only achieve a
maximum stable transduction efficiency of less than 25%, seven days
post transduction, with primary CD34 positive cord blood cells.
Strikingly, this 25% upper limit of transduction could not be
improved even after extremely high multiplicities of infection or
vector concentrations, such as a multiplicity of infection (MOI) of
up to 9000 and vector concentrations of up to 108 infectious units
per milliliter.
[0012] Follenzi et al. also used a very high MOI of 500 to
transduce cells in the presence of a three cytokine cocktail
containing interleukin-3 (IL-3), interleukin-6 (IL-6) and stem cell
factor (SCF). Interestingly, use of the cocktail would render the
cells unsuitable for human clinical transplantation.
[0013] Thus there remains a need to provide a more efficient means
of stably transducing cells with vectors at high frequency.
Additionally, there is a need for a more efficient means to
transduce non-stimulated cells for use both as research tools and
as a therapeutic agent.
[0014] Citation of the above documents is not intended as an
admission that any of the foregoing is pertinent prior art. All
statements as to the date or representation as to the contents of
these documents is based on the information available to the
applicant and does not constitute any admission as to the
correctness of the dates or contents of these documents.
DISCLOSURE OF THE INVENTION
[0015] The present invention provides highly efficient methods, and
compositions related thereto, for the stable transduction of cells
with viral vectors and viral particles. By "stable transduction,"
it is meant where an integrated form of the viral vector has been
inserted into the chromosomal DNA of the transduced cell. The
methods comprise exposing the cells to be transduced to contact
with at least one molecule that binds the cell surface. This
contacting step may occur prior to, during, or after the cells are
exposed to the viral vector or viral particle. Hereinafter, the
term "viral vector" will be used to denote any form of a nucleic
acid derived from a virus and used to transfer genetic material
into a cell via transduction. The term encompasses viral vector
nucleic acids, such as DNA and RNA, encapsidated forms of these
nucleic acids, and viral particles in which the viral vector
nucleic acids have been packaged.
[0016] The present invention also includes the use of the
transduced cells in other applications, including production of
useful gene products and proteins by expression of a nucleic acid
present in the vector or therapy of living subjects afflicted, or
at risk of being afflicted with a disease. Preferably, the subject
is human.
[0017] The at least one molecule that binds the surface of the
cells to be transduced includes any molecule that physically
interacts with a receptor, marker, or other recognizable moiety on
the surface of the cells. In principle, any cell surface binding
molecule may be used for high efficiency transduction of cells.
Without binding the invention to theory, the cell surface binding
molecules may result in the host cell's chromatin being more
receptive to DNA integration; in preferential integration of a
viral vector into a site favorable for vector gene expression; in
more efficient entry of the nucleic acid containing capsid into the
cytoplasm; in more efficient entry of the virus across the cell
membrane or internal membranous structures such as the endosome; or
in making the cell more permissive for nuclear import of the viral
vector's genetic material. The methods of the invention may also
involve more than one of the above possibilities. Also, and as
evident from the number and diversity of the above possibilities,
the invention cannot be limited to any one theory. Instead, and
given the extraordinary discovery of the invention in the stable
transduction of up to 100% of the treated cells without negatively
affecting the possible use of the cells in human therapy, the
invention should be viewed as opening a new approach in the field
of human cell therapy.
[0018] Not all cell surface binding molecules, however, will result
in the efficient and stable transduction by viral vectors. For
example, binding to a cell surface molecule that induces apoptosis
will not result in efficient transduction of the cell, but rather
cell death. Although cell death may be preferred for the killing of
cells (e.g. tumor cells) it is not preferred for the stable
transduction of cells with vectors containing payload genes or
nucleic acid sequences. A preferred cell surface binding molecule
results in the cell being more receptive to transduction by a viral
vector. Examples of such molecules include an antibody for a
specific cell surface receptor or portion thereof as well as a
ligand or binding domain for such a receptor. Moreover,
antigen-binding fragments of antibodies, such as F.sub.ab and
F.sub.v fragments are contemplated for use in the present
invention. The binding domain for the specific, cell-surface
receptor can contain a single epitope or two or more epitopes.
[0019] Preferred examples of cell surface binding molecules for use
in the invention are anti-CD3 and anti-CD28 antibodies which bind T
cells and make them more receptive to vector transduction. Other
preferred cell surface binding molecules are antibodies or ligands
for the FLT-3 ligand, TPO, and Kit ligand receptors, which make
cells expressing the receptors, such as hematopoietic stem cells,
more receptive to vector transduction. Additional preferred cell
surface binding molecules are antibodies or ligands for GM-CSF and
IL-4 receptors, which make dendritic cells or their precursors,
such as monocytes, CD34 positive stem cells, or their
differentiated progenitor cells on the dendritic cell lineage, more
receptive to vector transduction. Other cell surface binding
molecules include molecules found on cell surfaces which bind the
surface of another cell.
[0020] Additional examples of cell surface binding molecules
include polypeptides, nucleic acids, carbohydrates, lipids, and
ions, all optionally complexed with other substances. Preferably,
the molecules bind factors found on the surfaces of blood cells,
such as CD1a, CD1b, CD1c, CD1d, CD2, CD3.gamma., CD3.delta.,
CD3.epsilon., CD4, CD5, CD6, CD7, CD8.alpha., CD8p, CD9, CD10,
CD11a, CD11b, CD11 c, CDw12, CD13, CD14, CD15, CD15s, CD16a, CD16b,
CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28,
CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD39,
CD40, CD41, CD42a, CD42b, CD42c, CD42d, CD43, CD44, CD45, CD45R,
CD46, CD47, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD50,
CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CDw60, CD61,
CD62E, CD62L, CD62P, CD63, CD64, CD65, CD66a, CD66b, CD66c, CD66d,
CD66e, CD66f, CD67, CD68, CD69, CDw70, CD71, CD72, CD73, CD74,
CDw75, CDw76, CD77, CD79.alpha., CD79.beta., CD80, CD81, CD82,
CD83, CD84, CD85, CD86, CD87, CD88, CD89, CD90, CD91, CDw92, CD93,
CD94, CD95, CD96, CD97, CD98, CD99, CD100, CD101, CD102, CD103,
CD104, CD105, CD106, CD107a, CD107b, CDw108, CDw109, CD114, CD115,
CD116, CD117, CD118, CD119, CD120a, CD120b, CD121a, CD121b, CD122,
CD123, CDw124, CD125, CD126, CDw127, CDw128a, CDw128b, CDw130,
CDw131, CD132, CD133, CD134, CD135, CD136, CDw137, CD138, CD139,
CD140a, CD140b, CD141, CD142, CD143, CD144, CDw145, CD146, CD147,
CD148, CDw149, CD150, CD151, CD152, CD153, CD154, CD155, CD156,
CD157, CD158a, CD158b, CD161, CD162, CD163, CD164, CD165, CD166,
and TCR.zeta.. Small letters (e.g. "a" or "b") indicate complex CD
molecules composed of multiple gene products or belonging to
families of structurally related proteins. The notation "w" refers
to putative CD molecules that have not yet been fully confirmed. A
more complete listing of CD molecules is found in Kishimoto, T.
(ed). Current information on CD molecules is also found in Shaw, S.
(ed)., Protein Reviews on the Web: An International WWW
Resource/Journal at http://www.bsi.vt.edu/immunology.
[0021] More preferred are molecules that bind factors found on the
surfaces of lymphocytes, T cells and leukocytes, such as CD2,
CD3.gamma., CD3.delta., CD3.epsilon., CD5, CD6, CD7, CD8.alpha.,
CD8.beta., CD9, CD11a, CD18, CD25, CD26, CD27, CD28, CD29, CD30,
CD37, CD38, CD39, CD43, CD44, CD45R, CD46, CD48, CD49a, CD49b,
CD49c, CD49d, CD49e, CD49f, CD50, CD53, CD54, CD56, CD57, CD58,
CD59, CDw60, CD62L, CD68, CD69, CDw70, CD71, CD73, CDw75, CDw76,
CD84, CD85, CD86, CD87, CD89, CD90, CD94, CD96, CD97, CD98, CD99,
CD100, CD101, CD103, CD107a, CD107b, CDw108, CDw109, CD118, CD119,
CD120b, CD121a, CD122, CDw124, CDw127, CDw128a, CDw130, CD132,
CD134, CDw137, CD140a, CD140b, CD143, CD146, CD148, CD152, CD153,
CD154, CD155, CD161, CD162, CD165, CD166, and TCR.zeta..
[0022] Additional antibodies and molecules that bind to the surface
of cells, and suitable for use in the present invention, are
disclosed in Linscott's Directory of Immunological and Biological
Reagents, 11th Edition, January 2000, Publisher: W. D. Linscott,
Petaluma, Calif., which is hereby incorporated by reference as if
fully set forth. In some embodiments of the invention, however, the
cell surface binding molecule is not a cytokine.
[0023] While the invention may be practiced by use of soluble cell
surface binding molecules that promote vector transduction of
cells, other preferred embodiments include the use of immobilized
cell surface binding molecules. Preferably, the immobilized
molecules are antibodies. Alternatively, immobilization may be via
use of other cells that express the cell surface binding molecules.
A preferred method for the efficient transduction of hematopoietic
stem cells is to include bone marrow stromal cells, expressing
ligands on their surface that facilitate stem cell maintenance
without differentiation, during transduction. The stimulating cells
are not restricted to native cells, but any cell can be engineered
to express the appropriate cell surface binding molecule in order
to provide the correct stimulus for transduction.
[0024] Additional molecules that increase or reinforce the ability
of the at least one molecule to bind the cell surface may also be
included. For example, a soluble form of a (primary) antibody for a
specific cell surface receptor may be used in combination with a
secondary antibody that can crosslink primary antibodies already
bound to the cell surface.
[0025] Of course any cell can be used in the practice of the
invention. Preferably, the cell to be transduced is a eukaryotic
cell. More preferably, the cell is a primary cell. Cell lines,
however, may also be transduced with the methods of the invention
and, in many cases, more easily transduced. In one preferred
embodiment, the cell to be transduced is a primary lymphocyte (such
as a T lymphocyte) or a macrophage (such as a monocytic
macrophage), or is a precursor to either of these cells, such as a
hematopoietic stem cell. Other preferred cells for transduction in
general are cells of the hematopoietic system, or, more generally,
cells formed by hematopoiesis as well as the stem cells from which
they form and cells associated with blood cell function. Such cells
include granulocytes and lymphocytes formed by hematopoiesis as
well as the progenitor pluripotent, lymphoid, and myeloid stem
cells. Cells associated with blood cell function include cells that
aid in the functioning of immune system cells, such as antigen
presenting cells like dendritic cells, endothelial cells, moncytes,
and Langerhans cells. In a preferred embodiment, the cells are T
lymphocytes (or T cells), such as those expressing CD4 and CD8
markers.
[0026] In particularly preferred embodiments, the cell is a primary
CD4+ T lymphocyte or a primary CD34+ hematopoietic stem cell.
However, and given that the viral vectors for use in the invention
may be pseudotyped with Vesicular Stomatitis Virus envelope G
protein (as discussed below), any cell can be transduced via the
methods of the present invention. Such a cell includes, but is not
limited to, an astrocyte, a skin fibroblast, a epithelial cell, a
neuron, a dendritic cell, a lymphocyte, a cell associated with the
immune response, a vascular endothelial cell, a tumor cell, a tumor
vascular endothelial cell, a liver cell, a lung cell, a bone marrow
cell, an antigen presenting cell, a stromal cell, an adipocyte, a
muscle cell, a pancreatic cell, a kidney cell, an ovum or
spermatocyte (e.g. to create transgenic animals), a cell that
contributes to the germ line, a embryonic pluripotential stem cell
or its progenitors, a blood cell including non-nucleated cells such
as platelets and erythrocytes, and the like. Preferably, the cell
is of a eukaryotic, multicellular species (e.g., as opposed to a
unicellular yeast cell), and, even more preferably, is of mammalian
origin, e.g., a human cell.
[0027] A cell to be transduced can be present as a single entity,
or can be part of a larger collection of cells. Such a "larger
collection of cells" can comprise, for instance, a cell culture
(either mixed or pure), a tissue (e.g., epithelial, stromal or
other tissue), an organ (e.g., heart, lung, liver, gallbladder,
urinary bladder, eye, and other organs), an organ system (e.g.,
circulatory system, respiratory system, gastrointestinal system,
urinary system, nervous system, integumentary system or other organ
system), a blastocyst, a embryonic stem cell a cell from a fetus
(e.g. for the treatment of a genetic disorder/disease or for
creating transgenic animals), diseased tissues such as a tumor or
the site of an infection, or an organism (e.g., a bird, mammal,
marine organism, fish, plant or the like). Preferably, the
organs/tissues/cells being targeted are of the circulatory system
(including for example, but not limited to heart, blood vessels,
and blood), respiratory system (e.g., nose, pharynx, larynx,
trachea, bronchi, bronchioles, lungs, and the like),
gastrointestinal system (including for example mouth and oral
tissues, pharynx, esophagus, stomach, intestines, salivary glands,
pancreas, liver, gallbladder, and the like), mammary system (such
as breast epithelial cells and supporting cells in the tissue),
urinary system (such as kidneys, ureters, urinary bladder, urethra,
and the like), nervous system (including, but not limited to, brain
and spinal cord, and special sense organs, such as the eye) and
integumentary system (e.g., skin).
[0028] Even more preferably, the cells to be transduced are
selected from the group consisting of heart, blood vessel,
including tumor blood vessels and blood vessels associated with
infected or diseased tissue, bone marrow, blood, brain, lymphatic
tissue, lymph node, spleen, lung, liver, gallbladder, urinary
bladder, and eye cells. In one particular embodiment of the
invention, the cell is autologous to the intended host for use, but
cells allogenic, partially mismatched, completely mismatched, or
even xenogenic to the host may also be used. Furthermore, universal
donor cells, suitable for use in any given host organism, a related
group of organisms or a species, such as human beings, may be
transduced. This latter embodiment of the invention is particularly
important in the transplantation of cells, tissues or organs, where
the source of the transduced cells may be critical to the outcome
of the transplant.
[0029] Another preferred cell for transduction by the methods of
the invention is a tumor cell, a diseased cell, or a cell at risk
for becoming abnormal over time due to its genetic makeup or the
genetic makeup of other cells present in the same organism. The
latter embodiment permits the transduced cells of the invention to
be used in prophylaxis. Breast cancer is one example of a disease
process where prognostic indicators would allow for treatment with
the transduced cells of the invention as early genetic intervention
before the disease ensues. However, the methods of the invention
may also be used in the therapeutic treatment of breast cancer
after the disease has been detected. Additional applications of the
invention in cancer therapy are numerous, and one skilled in the
art would be able to use the invention set out herein for the
treatment of many types of cancers without undue
experimentation.
[0030] By way of example, and without limiting the present
invention, one application is in breast cancers that are estrogen
dependent. The cancer cells in estrogen-dependent breast cancer
would be preferentially transduced by using antibodies or ligands
that bind the estrogen receptor in combination with a therapeutic
viral vector. The vector may contain, for example, a tumor
inhibiting gene, such as the Herpes virus thymidine kinase gene.
The transduced cells can thus be selectively killed by the addition
of gancyclovir, a pro-drug that can be activated by Herpes
thymidine kinase. Additional examples of tumor inhibiting genes and
a corresponding pro-drug are numerous and well known in the art and
may be selected by the skilled artisan without undue
experimentation. The use of activatable pro-drugs in combination
with application of the transduction methods of the invention may
be broadly applied to other tumor types, and the above example does
not limit the invention to tumors that are hormonal dependent or
dependent upon some soluble factor for growth or proliferation.
[0031] For example, Her-2/neu positive tumor cells are not estrogen
dependent, and a poor prognostic indicator since non-estrogen
dependent tumors containing such cells are highly resistant to
treatment with drugs such as taxol, an estrogen antagonist. A
preferred embodiment to the invention is to include antibodies or
other molecules that bind Her2/neu or heregulin with viral vector
preparations during transduction of tumor contaminated cells, such
as in a bone marrow transplantation protocol. Alternatively, the
transduction may be made directly to the tumor site, or intra
vascularly in vivo with vectors that would modulate
tumorigenesis.
[0032] Yet another embodiment of the invention is to target the
tumor vasculature, alone or in combination with targeting the tumor
cells. St Croix et al., which is hereby incorporated by reference
as if fully set forth, have identified genes that are specifically
overexpressed in tumor endothelial cells as compared to normal
endothelium by SAGE analysis. Many of these genes encode cell
surface molecules, such as the Thy-1 cell surface antigen or
Endo180 lectin. All of the upregulated cell surface factors may be
bound by a cell surface binding molecule of the invention to
provide a stimulus for efficient stable gene transduction. Thus, an
approach for tumor therapy would be to destroy the tumor
vasculature by killing tumor endothelial cells after transducing
them with a therapeutic viral vector in the presence of cell
surface binding molecules that bind selectively to tumor
vasculature and not normal endothelial cells.
[0033] In yet another embodiment of the invention is selective
expression of an anti-tumor gene in tumor vasculature by
incorporating elements (e.g. promoters or cis-acting
stabilizing/degradation elements on mRNA) in the viral vector that
selectively promote expression of the anti-tumor gene in tumor but
not in normal vascular endothelium. Such methods can occur ex vivo,
in vitro or in vivo. In vivo is the preferred method for therapy if
the tumor vascular endothelium is targeted. Alternatively, and if
the goal is to purge bone marrow of contaminating tumor cells for
bone marrow transplantation, for example, then the preferred method
for therapy occurs ex vivo or in vitro.
[0034] Furthermore, in vivo uses are not restricted to disease
states and can be used to transduce normal cells. For example, the
invention may be used to transduce hematopoietic stem cells in vivo
in the bone marrow. Any combination of antibodies or other cell
surface binding molecules, such as FLT-3 ligand, TPO and Kit
ligand, or functional analogs thereof, or stromal cells expressing
the cell surface binding molecule, could be added with vector upon
direct injection into the bone marrow for high efficiency bone
marrow transduction. The term "functional analog" refers to any
molecule that retains the cell surface binding activity of a cell
surface binding molecule of the invention. Such functional analogs
include fragments of FLT-3 ligand, TPO and Kit ligand; FLT-3
ligand, TPO and Kit ligand molecules containing one or more amino
acid substitutions, additions or deletions; and antibodies that
mimic the cell surface binding activity of a cell surface binding
molecule.
[0035] An alternative approach to the above is to use bone marrow
stromal cells as producer cells for the viral vector and thus
provide the vector and cell surface binding molecule via cell
therapy and not as a vector preparation. Another example is the
transduction of T cells or dendritic cells by adding functional
analogs of CD3 and CD28 antibodies or GM-CSF and IL-4,
respectively, with vector during subcutaneous injection. The lymph
in the subcutaneous tissue would drain the vector and stimulants
into the lymph nodes for efficient transduction of the targeted
cells.
[0036] The present invention includes the advantage that
optionally, purification of the cell to be transduced is not
essential. Transduction of mainly a cell type of interest can be
accomplished by the choice of cell surface moiety to be bound. Thus
in a mixed population of blood cells, for example, transduction of
cells expressing CD3, such as certain T cells, will be enhanced
when CD3 specific antibodies are used to interact with the cells.
This will occur in preference over other cell types in the
population, such as granulocytes and monocytes that do not express
CD3.
[0037] The invention also encompasses the transduction of purified
or isolated cell types if desired. The use of a purified or
isolated cell type provides additional advantages such as higher
efficiencies of transduction due to higher vector concentrations
relative to the cell to be transduced.
[0038] When purified T cells are to be transduced, the at least one
molecule preferably binds a cell surface molecule found on T cells.
Examples of such cell surface molecules include CD3, CD28, CD25,
CD71, and CD69. Examples of molecules that bind to these cell
surface molecules include antibodies and monoclonal antibodies that
recognize them, many of which are commercially available or readily
and routinely prepared using standard techniques without undue
experimentation. In a preferred embodiment for the transduction of
CD4+ or CD8+ cells, monoclonal antibodies that recognize CD3 and/or
CD28 may be used. Commercially available examples of such
antibodies include OKT3 for CD3 and CD28.2 for CD28. These antibody
molecules may be used in a soluble form, optionally later
crosslinked by other molecules, or in an immobilized form such as
on beads or other solid surfaces. In a particularly preferred
embodiment of the invention, the antibodies are immobilized on the
surface of the vessel, such as the walls of a tissue culture well,
plate, or bag used for the viral vector mediated transduction.
Without being bound by theory, use of immobilized antibodies on the
surface where cells adhere or make contact may increase local
concentrations of cell surface interactions on the cell
surface.
[0039] When hematopoietic stem cells are to be transduced,
antibodies specific for the hematopoietic stem cell receptor of the
FLT-3 ligand, TPO (Thrombopoietin or Megakaryocyte Growth and
Development Factor), or Kit ligand may be used as the cell surface
binding molecule. Alternatively, antibodies to stem cell positive
cell markers, including, but not limited to CD34 or AC133, may be
used. When a ligand containing compound or composition is used as a
cell surface binding molecule, the whole native ligand-containing
proteins, ligands or ligands bound to heterologous proteins can be
used either in a soluble or immobilized form. Immobilized forms
include attachment to microbeads, directly or indirectly, using,
for example, avidin/biotin.
[0040] Alternatively, the ligand may be expressed in the viral
envelope of the viral vector, optionally in the form of a chimeric
or fusion proteins, and/or complexed (covalently or non-covalently)
with one or more other protein(s). In such embodiments, the cell
surface binding molecule is presented in combination with the viral
vector as a single composition for transducing cells. Additional
examples of cell surface binding molecules that may be expressed in
viral envelopes include the numerous surface factors listed
above.
[0041] Other preferred cell surface binding molecules, such as
antibodies or fragments thereof, are those that bind to the
hematopoietic stem cell receptors of Notch or Delta, or the Notch
or Delta proteins themselves, or the ligands of Notch or Delta that
are bound to heterologous proteins. Delta and Notch encode cell
surface proteins that influence a wide variety of cell fate
decisions in Drosophila development. Vertebrate homologues of Delta
and Notch are essential for normal embryonic development. Delta
homologues are importantly involved in the regulation of
hematopoiesis. Delta-Serrate-lag2 (DSL), a soluble form of a
homologue, enhances expansion of primitive hematopoietic
precursors. When combined with hematopoietic growth factors,
including interleukin-3 (IL-3), granulocyte colony-stimulating fact
or (G-CSF) or granulocyte-macrophage colony-stimulating factor
(GM-CSF), DSL promotes the expansion of primitive hematopoietic
progenitors and at the same time inhibited the differentiation of
primitive precursors into more mature precursor cells responsive to
IL-3 alone (see Han et al.). DSL most likely acts by activating the
Notch receptor expressed in hematopoietic cells, modulating
cellular competence to respond to conventional hematopoietic growth
factors by selectively blocking cell differentiation, but not
proliferation signals (see Han and Moore, Blood 1999). Therefore,
Delta and Notch homologues, antibodies that are functional analogs
to the homologues, are further preferred cell surface binding
molecules for use in achieving greater than 75% efficient vector
transduction of cells, particularly hematopoietic stem cells.
[0042] The present invention includes viral vectors, and
compositions comprising them, for use in the disclosed methods. The
vectors are preferably retroviral (family Retroviridae) vectors,
and more preferably lentiviral vectors. Other retroviral vectors,
such as oncoviral and murine retroviral vectors, may also be used.
Additional vectors may be derived from other DNA viruses or viruses
that can convert their genomes into DNA during some point of their
life cycle. Preferably the viruses are from the families
Adenoviridae, Parvoviridae Hepandaviridae (including the hepatitis
delta virus and the hepatitis E virus which is not normally
classified in the Hepandaviridae), Papoviridae (including the
polyomavirinae and the papillomavirinae), Herpesviridae, and
Poxyiridae.
[0043] Additional viruses of the family Retroviridae (i.e., a
retrovirus), are of the genus or subfamily Oncovirinae,
Spumavirinae, Spumavirus, Lentivirinae, and Lentivirus. An RNA
virus of the subfamily Oncovirinae is desirably a human
T-lymphotropic virus type 1 or 2 (i.e., HTLV-1 or HTLV-2) or bovine
leukemia virus (BLV), an avian leukosis-sarcoma virus (e.g., Rous
sarcoma virus (RSV), avian myeloblastosis virus (AMV), avian
erythroblastosis virus (AEV), and Rous-associated virus (RAV; RAV-0
to RAV-50), a mammalian C-type virus (e.g., Moloney murine leukemia
virus (MuLV), Harvey murine sarcoma virus (HaMSV), Abelson murine
leukemia virus (A-MuLV), AKR-MuLV, feline leukemia virus (FeLV),
simian sarcoma virus, reticuloendotheliosis virus (REV), spleen
necrosis virus (SNV)), a B-type virus (e.g., mouse mammary tumor
virus (MMTV)), and a D-type virus (e.g., Mason-Pfizer monkey virus
(MPMV) and "SAIDS" viruses).
[0044] An RNA virus of the subfamily Lentivirus is desirably a
human immunodeficiency virus type 1 or 2 (i.e., HIV-1 or HIV-2,
wherein HIV-1 was formerly called lymphadenopathy associated virus
3 (HTLV-III) and acquired immune deficiency syndrome (AIDS)-related
virus (ARV)), or another virus related to HIV-1 or HIV-2 that has
been identified and associated with AIDS or AIDS-like disease. The
acronym "HIV" or terms "AIDS virus" or "human immunodeficiency
virus" are used herein to refer to these HIV viruses, and
HIV-related and -associated viruses, generically. Moreover, a RNA
virus of the subfamily Lentivirus preferably is a Visna/maedi virus
(e.g., such as infect sheep), a feline immunodeficiency virus
(FIV), bovine lentivirus, simian immunodeficiency virus (SIV), an
equine infectious anemia virus (EIAV), and a caprine
arthritis-encephalitis virus (CAEV).
[0045] A particularly preferred lentiviral vector is one derived
from HIV, most preferably HIV-1, HIV-2, or chimeric combinations
thereof. Of course different serotypes of retroviruses, especially
HIV, may be used singly or in any combination to prepare vectors
for use in the present invention. Preferred vectors of the
invention contains cis acting elements that are present in the
wild-type virus, but not present in a "basic" lentiviral vector. A
"basic" lentiviral vector contains minimally, LTRs and packaging
sequences in the 5' leader and gag encoding sequences, but can also
optionally contain the RRE element to facilitate nuclear export of
vector RNA in a Rev dependent manner. A preferred vector
additionally contains nucleotide sequences that enhance the
efficiency of transduction into cells.
[0046] An example of such a vector is pN2cGFP, a vector that
contains the complete sequences of gag and pol. Another example is
a vector that contain sequences from about position 4551 to
position 5096 in pol (reference positions from the pNL4-3 sequence,
Accession number M19921, HIVNL43 9709 bp, kindly provided by C. E.
Buckler, NIAID, NIH, Bethesda, Md.). However any cis-acting
sequence from the wt-HIV that can improve vector transduction
efficiency may be used. Other examples of vectors capable of
efficient transduction via the present invention are cr2HIV
constructs as described in U.S. Pat. No. 5,885,806.
[0047] A previously identified sequence that is insufficient to
significantly increase transduction efficiency described by Zennou
et al. (2000) as a central DNA flap (a 178 base pair fragment from
positions 4793 to 4971 on pLAI3, corresponding to positions 4757 to
4935 on pNL4-3) capable of increasing transduction efficiency. The
present invention includes the discovery that while this small
fragment is not sufficient to increase the transduction efficiency,
a larger 545 base pair fragment (positions 4551 to 5096 in pNL4-3),
or yet larger fragments containing it, was capable of increasing
transduction as part of the present invention.
[0048] Additional examples of viral vector constructs that may be
used in the present invention are found in U.S. Pat. No. 5,885,806,
which is hereby incorporated by reference as if fully set forth.
The constructs in U.S. Pat. No. 5,885,806 are merely examples that
do not limit the scope of vectors that efficiently transduce cells.
Instead, the constructs provide additional guidance to the skilled
artisan that a viral vector for use with the present invention may
contain minimal sequences from the wild-type virus or contain
sequences up to almost the entire genome of wild-type virus, yet
exclude an essential nucleic acid sequence required for replication
and/or production of disease. Methods for determining precisely the
sequences required for efficient transduction of cells are routine
and well known in the art. For example, a systematic incorporation
of viral sequences back into a "basic" vector or deleting sequences
from vectors that contain virtually the entire HIV genome, such as
cr2HIVs, is routine and well known in the art.
[0049] Furthermore, placing sequences from other viral backbones
into viral vectors of interest, such as the cytomegalovirus (CMV),
is also well known in the art. Regardless of the actual viral
vector used, various accessory proteins encoded by, and sequences
present in, the viral genetic material may be left in the vector or
helper genomes if these proteins or sequences increase transduction
efficiency in certain cell types. Numerous routine screens are
available to determine whether certain genetic material increases
transduction efficiency by incorporating the sequence in either the
vector or helper genomes. A preferred embodiment of the invention
is to not include accessory proteins in either the vector or helper
genomes. But this preference does not exclude embodiments of the
invention where accessory proteins and other sequences are left in
either the vector or a helper genome to increase transduction
efficiency.
[0050] The viral vectors used in the present invention may also
result from "pseudotype" formation, where co-infection of a cell by
different viruses produces progeny virions containing the genome of
one virus encapsulated within an outer layer containing one or more
envelope protein of another virus. This phenomenon has been used to
package viral vectors of interest in a "pseudotyped" virion by
co-transfecting or co-infecting a packaging cell with both the
viral vector of interest and genetic material encoding at least one
envelope protein of another virus or a cell surface molecule. See
U.S. Pat. No. 5,512,421. Such mixed viruses can be neutralized by
anti-sera against the one or more heterologous envelope proteins
used. One virus commonly used in pseudotype formation is the
vesicular stomatitis virus (VSV), which is a rhabdovirus. The use
of pseudotyping broadens the host cell range of the virus by
including elements of the viral entry mechanism of the heterologous
virus used.
[0051] Pseudotyping of viral vectors and VSV for use in the present
invention results in viral particles containing the viral vector
nucleic acid encapsulated in a nucleocapsid which is surrounded by
a membrane containing the VSV G protein. The nucleocapsid
preferably contains proteins normally associated with the viral
vector. The surrounding VSV G protein containing membrane forms
part of the viral particle upon its egress from the cell used to
package the viral vector. Examples of packaging cells are described
in U.S. Pat. No. 5,739,018. In a preferred embodiment of the
invention, the viral particle is derived from HIV and pseudotyped
with VSV G protein. Pseudotyped viral particles containing the VSV
G protein can infect a diverse array of cell types with higher
efficiency than amphotropic viral vectors. The range of host cells
include both mammalian and non-mammalian species, such as humans,
rodents, fish, amphibians and insects.
[0052] The viral vector for use in the transduction methods of the
invention can also comprise and express one or more nucleic acid
sequences under the control of a promoter present in the virus or
under the control of a heterologous promoter introduced into the
vector. The promoters may further contain insulatory elements, such
as erythroid DNAse hypersensitive sites, so as to flank the operon
for tightly controlled gene expression. Preferred promoters include
the HIV-LTR, CMV promoter, PGK, U1, EBER transcriptional units from
Epstein Barr Virus, tRNA, U6 and U7. While Pol II promoters are
preferred, Pol III promoters may also be used. Tissue specific
promoters are also preferred embodiments. For example, the beta
globin Locus Control Region enhancer and the alpha & beta
globin promoters can provide tissue specific expression in
erythrocytes and erythroid cells. Another further preferred
embodiment is to use cis-acting sequences that are associated with
the promoters. For example, The U1 gene may be used to enhance
antisense gene expression where non-promoter sequences are used to
target the antisense or ribozymes molecule to a target spliced RNA
as set out in U.S. Pat. No. 5,814,500, which is hereby incorporated
by reference.
[0053] Of course any cis acting nucleotide sequences from a virus
may be incorporated into the viral vectors of the invention. In
particular, cis acting sequences found in retroviral genomes are
preferred. For example, cis-acting nucleotide sequence derived from
the gag, pol, env, vif, vpr, vpu, tat or rev genes may be
incorporated into the viral vectors of the invention to further
increase tranduction efficiency. Preferably, a cis acting sequence
does not encode an expressed polypeptide; is not expressed as a
polypeptide or part thereof due to genetic alteration, such as
deletion of a translational start site; encodes only a portion or
fragment of a larger polypeptide; or is a mutant sequence
containing one or more substitutions, additions, or deletions from
the native sequence. An example of a cis acting sequence is the
cPPT (central polypurine tract) sequence identified within the HIV
pol gene.
[0054] Said one or more nucleic acid sequences in the viral vectors
of the invention may be found in the virus from which the vector is
derived or be a heterologous sequence. The sequence is preferably a
full-length or partial sequence that is or encodes a gene product
of interest. Such sequences and gene products are preferably
biologically active agents capable of producing a biological effect
in a cell. Examples of such agents include proteins, ribonucleic
acids, enzymes, transporters or other biologically active
molecules.
[0055] In one preferred embodiment, the agent is a protein, such as
a toxin, transcription factor, growth factor or cytokine,
structural protein, or a cell surface molecule. The protein may
contain one or more domains for which no function has been
identified and may be homologous to the transduced cell.
Additionally, the protein may be absent, deficient or altered in
the cell to be transduced. Alternatively, the protein may be a
transdominant negative mutant or a decoy to prevent a natural
protein from carrying out its normal activity in the transduced
cell.
[0056] For example, the nucleic acid sequence may code for a
ribozyme that binds, cleaves and destroys RNA expressed, or to be
expressed, in the transduced cell. Alternatively, the nucleic acid
sequence may code for an antisense molecule designed to target a
particular nucleic acid sequence and result in its degradation. The
vector contained sequence may be overexpressed, inducibly
expressed, or under cellular or viral regulatory transcription
control in the transduced cell. Depending on the intended use, the
heterologous sequence may encode any desired protein including a
marker for transduced cells. Such markers include selectable
markers such as a particular resistance phenotype, such as
neomycin, MDR-1 (P-glycoprotein),
O.sup.6-methylguanine-DNA-methyltransferase (MGMT), dihydrofolate
reductase (DHFR), aldehyde dehydrogenase (ALDH),
glutathione-S-transferase (GST), superoxide dismutase (SOD) and
cytosine deaminase. See Koc et al., which is hereby incorporated by
reference, for a review.
[0057] In the methods of the invention, the cells to be transduced
are exposed to contact with the at least one molecule that binds
the cell surface before, after, or simultaneously with application
of the viral vector. For example, the cells can be cultured in
media with CD3 and CD28 antibodies (coated onto the surface of the
culture dish or immobilized on beads present in the culture)
before, after, or in the presence of the viral vector to be
transduced. Preferably, the cells are exposed to immobilized CD3
and/or CD28 only after or only upon initial contact with the viral
vector. Under these conditions, the cells are not exposed to cell
surface binding molecule(s) prior to actual transduction with the
viral vector. In embodiments where contact with a cell surface
binding molecule occurs after exposure of the cells to a viral
vector (transduction), the contact preferably occurs within three
days of transduction, more preferably within one to two days after
transduction.
[0058] Incubation of the cells with the viral vector may be for
different lengths of time, depending on the conditions and
materials used. Factors that influence the incubation time include
the cell, vector and MOI (multiplicity of infection) used, the
molecule(s) and amounts used to bind the cell surface, whether and
how said molecule(s) are immobilized or solubilized, and the level
of transduction efficiency desired. Preferably, the incubation is
for about eight to about 72 hours, more preferably for about 12 to
about 48 hours. In a particularly preferred embodiment, the
incubation is for about 24 hours and is optionally repeated
once.
[0059] Contact between the cells to be transduced and a viral
vector occurs at least once, but it may occur more than once,
depending upon the cell type. For example, high efficiency
transduction of CD34 positive stem cells have been accomplished
with multiple transductions with vector. A preferred method of the
invention is to simultaneously introduce a viral vector in
combination with a cell surface binding molecule (e.g. CD3 and/or
CD28 antibodies or a FLT-3 ligand, TPO or Kit ligand) and avoid
changing the medium for between about one and about eight days
after transduction. More preferably, the medium is not changed for
three days post transduction. Transduction can proceed for as long
as the conditions permit without the process being significantly
detrimental to the cells or the organism containing them.
Additional examples of cell surface binding proteins for such use
include those described hereinabove.
[0060] Similarly, the MOI used is from about 1 to about 400,
preferably less than 500. Generally, the preferred MOI is from
about 2 to about 50. More preferably, the MOI is from about 10 to
about 30, although ranges of from about 1 to about 10, about 20,
about 30, or about 40 are also contemplated. Most preferred is an
MOI of about 20. Furthermore, the copy number of viral vector per
cell should be at least one. However, many copies of the vector per
cell may also be used with the above described methods. The
preferred range of copies per cell is from about 1 to about 100.
The more preferred copy number is the minimum copy number that
provides a therapeutic, prophylactic or biological impact resulting
from vector transduction or the most efficient transduction.
[0061] For therapeutic or prophylactic applications, a more
preferred copy number is the maximum copy number that is tolerated
by the cell without being significantly detrimental to the cell or
the organism containing it. Both the minimum and maximum copy
number per cell will vary depending upon the cell to be transduced
as well as other cells that may be present. The optimum copy number
is readily determined by those skilled in the art using routine
methods. For example, cells are transduced at increasing increments
of concentration or multiplicities of infection. The cells are then
analyzed for copy number, therapeutic or biological impact and for
detrimental effects on the transduced cells or a host containing
them (e.g. safety and toxicity).
[0062] After incubation with the viral vector in vitro, the cells
may be cultured in the presence of the cell surface binding
molecule(s) for various times before the cells are analyzed for the
efficiency of transduction or otherwise used. Alternatively, the
cells may be cultured under any conditions that result in cell
growth and proliferation, such as incubation with interleukin-2
(IL-2) or incubation with the cell surface binding molecule(s)
followed by IL-2. Post transduction incubation may be for any
period of time, but is preferably from about one to about seven to
ten days. Longer periods of time, such as about 14 days, may also
be used, although periods that are detrimental to cell growth are
not preferred. In embodiments of the invention where the cells are
cultured with the cell surface binding molecule(s) before
incubation with the viral vector, the culture times may range from
about 24 to about 72 hours, most preferably 24 hours.
[0063] Such pre-transduction culturing may be compared to
stimulation of cells, with cytokines and/or mitogens for example,
prior to transduction as taught in the art. The present invention
includes advantages resulting from the avoidance of such
stimulation. For example, stimulation expands the numbers of cells
through proliferation to result in many more cells post-stimulation
than pre-stimulation. Transduction of this expanded set of cells
requires much more viral vector and related transduction materials
(e.g. containers, media, cytokines etc), increasing the associated
cost. Furthermore, the stimulation of cells affects their quality
for further applications. Movassagh et al. describe the use of a
three day pre-transduction stimulation that resulted in
deterioration of the T cell repertoire diversity after transduction
and further culturing. Additionally, pre-transduction stimulation
removes the advantage available from the transduction of cells that
are not actively dividing.
[0064] The efficiency of transduction observed with the present
invention is from about 75-100%. Preferably, the efficiency is at
least about 75 to 90%. More preferred embodiments of the invention
are where transduction efficiency is at least about 90 to 100%.
Most preferred embodiments have transduction efficiencies of at
least 91, 92, 93, 94, 95, 96, 97, 98, 99 and 100%.
[0065] In addition to the above, the transduced cells may be used
in research or for treatment or prevention of disease conditions in
living subjects. An example of a research use is the
structure-function studies described by Unutmaz et al. Therapeutic
uses for the transduced cells include the introduction of the cells
into a living organism. For example, unstimulated primary T cells
isolated from an individual infected with, or at risk of being
infected with HIV, may be first transduced by a vector, like that
described in U.S. Pat. No. 5,885,806, using the present methods and
followed by injection of the transduced cells back into the
individual. Alternatively, the cells may be used directly for the
expression of a heterologous sequence present in the viral
vector.
[0066] When used as a part of HIV therapy or prophylaxis, the
vector may encode a toxin or other anti-viral agent that has been
adapted for anti-HIV applications. Alternatively, the vector may
encode an agent designed to target HIV, such as transdominant
negative mutants of the tat, rev, nef, vpu, or vpr genes. In other
applications the transduced cell may be corrected to express an
appropriate globin gene to correct sickle cell anemia or
thalassaemia. Immune cells may also be transduced to modulate their
immune function, their response to antigen, or their interactions
with other cells. The skilled artisan is aware of the above uses
for the present transduction methods as well as numerous other uses
and applications known in the art.
BRIEF DESCRIPTION OF THE FIGURES
[0067] FIGS. 1A and 1B show maps of pN2cGFP and pN1GFP(cPT),
respectively. Various restriction enzyme sites are indicated as
well as the components derived from HIV. The pN2cGFP construct
contains the GFP coding sequence operably linked to a CMV
(cytomegalovirus) promoter, thus controlling GFP expression. The
pN1GFP(cPT) construct is also referred to as pN1(cpt)CGFP below and
contains the cPPT from the HIV pol gene. These constructs are used
in the examples described below.
[0068] FIG. 2 shows the results of transduction of primary T cells
using beads coated with immobilized CD3 and CD28 antibodies. The
cells were either contacted with vector before contact with the
beads (Panel A), contacted with the beads prior to contact with the
vector (Panel B), or simultaneously contacted with both vector and
beads (Panel C). The flow cytometry results based on fluorescence
from GFP encoded by the transduced vector indicate that the cells
in Panels A-C were transduced 90.70, 87.19, and 79.14%,
respectively.
[0069] FIG. 3 shows a comparison of transduction using either IL-2
and PHA-P or bead immobilized CD3 and CD28 antibodies to stimulate
CD4+ cells before contact with viral vector. The use of immobilized
antibodies resulted in transduction efficiencies of over 95% each
time. The use of IL-2 and PHA resulted on efficiencies of only 70.2
to 84.5%.
[0070] FIG. 4 is a depiction of the frequency of human CD4+ T cell
transduction using the present methods. Fifteen days post
transduction, a comparison of flow cytometry analysis of control
cells versus cells transduced with a vector capable of expressing
green fluorescent protein (GFP) at a MOI of 20 shows that about 93%
of the transduced cells also exhibit green fluorescence.
[0071] FIG. 4 shows the results of FACS analysis for CD4+ and GFP+
cells at 14 days post transduction using either IL-2 and PHA-P or
bead immobilized CD3 and CD28 antibodies. Approximately 93% of the
antibody treated cells remained stably transduced after 14 days.
Only about 75% of cells treated with IL-2 and PHA remained stably
transduced after that time.
[0072] FIG. 5 shows the results of cells transduced with different
viral vectors.
[0073] FIG. 6 shows the effect from the use of different MOIs on
transfection efficiency.
[0074] FIG. 7 demonstrates the stable transduction of CD34+ cells
prepared from umbilical cord blood after multiple transductions
with a viral vector in the presence of cell surface binding
molecules. Over 88% of cells remained positive after over 6 weeks
post transduction.
[0075] FIG. 8, panels A-D, shows the efficiency of long term
transduction after transplantation to SCID (severe combined
immunodeficiency) mice. After approximately eight weeks, an average
of over 91% of the transduced cells, which continued to mature,
remained positive for expression of the transduced GFP marker.
[0076] FIG. 9, panels A and B, shows the efficiency of dendritic
cell transduction after seven days.
MODES OF CARRYING OUT THE INVENTION
[0077] The present invention is directed to methods, and
compositions related thereto, for the stable transduction of cells
with viral vectors to efficiencies of greater than about 75%.
Stably transduced cells may be distinguished from transiently
transduced, or pseudotransduced cells, after about seven to ten
days, or optionally after about 14 days, post transduction. The
methods relate to the fact that contact of the cells to be
transduced with at least one molecule that binds the cell surface
increases the efficiency of stable transduction. Surprisingly, the
contacting step may occur after the transduction step. Even more
surprisingly, the highest levels of stable transduction were seen
when transduction occurred first followed by contact with
immobilized cell surface binding molecules.
[0078] The methods of the invention comprise the step of
transduction with a viral vector in combination with contact with a
cell surface binding molecule. As noted above, the contact may
occur before, after or at the same time as transduction with the
vector. The invention is broadly applicable to any cell, and the
use of any cell surface binding molecule. Cells for use with the
present methods include unstimulated primary cells, which are
freshly isolated from an in vivo source as well as cell lines,
which may have been previously cultured for various times in the
presence of factors which maintain them in a proliferating state.
When cell lines are used, they may be first cultured in the absence
of stimulatory factors prior to transduction with the present
methods.
[0079] In the case of primary cells, they are first obtained from
an in vivo source followed optionally by selection for particular
cell types. For example, if primary CD4+ and/or CD8+ T cells are to
be used, peripheral blood (PB) or cord blood ("CB" from an
umbilical source) samples are first obtained followed by enrichment
for CD4+ and/or CD8+ cell types. Standard magnetic beads positive
selection, plastic adherence negative selection, and/or other art
recognized standard techniques may be used to isolate CD4+ and/or
CD8+ cells away from contaminating PB cells. Purity of the isolated
cell types may be determined by immunophenotyping and flow
cytometry using standard techniques.
[0080] After isolation, the primary cells may be used in the
present methods to be transduced with viral vectors at efficiencies
of greater than 75%. The invention is most advantageously used with
primary lymphocytes, such as T cells, transduced with an HIV-1
based vector capable of expressing heterologous genetic material of
interest. Another preferred use is with primary hematopoietic stem
cells, such as CD34 positive cells. In cases where the heterologous
genetic material is or encodes a therapeutic or prophylactic
product for use in vivo to treat or prevent a disease, the
transduced primary cell can be introduced back into an in vivo
environment, such as a patient. As such, the invention contemplates
the use of the transfected cells in gene therapy to treat, or
prevent, a disease by combating a genetic defect or targeting a
viral infection.
[0081] The invention is also contemplated for use in efficiently
transducing cells for determining the function of a gene,
expressing genes efficiently in mammalian cells, expressing genetic
libraries (cDNA libraries and genetic antisense or ribozymes
libraries) for functional screening for genes of interest, use in
protein-protein or protein-nucleic acid two-hybrid like detection
strategies, gene trapping approaches, high-throughput gene
screening analysis with a microarray or protein array, or studies
employing SAGE, proteomics and other functional analytical
methods.
[0082] For the transduction of primary cells in a mixed population,
the above isolation/purification steps would not be used. Instead,
the cell to be transduced would be targeted by selection of at
least one appropriate cell surface molecule or moiety found on that
cell type and the preparation of one or more molecules capable of
binding said moiety. The cell surface moiety may be a receptor,
marker, or other recognizable epitope on the surface of the
targeted cells. Once selected, molecules that interact with the
moiety, such as specific antibodies, may be prepared for use in the
present invention.
[0083] For example, CD4+ and/or CD8+ cells can either be first
purified and then transduced by the methods of the invention with
the use of immobilized CD3 and CD28 antibodies or alternatively be
transduced as part of a mixed population, like peripheral blood
cells (PBCs) or peripheral blood mononuclear cells (PBMNCs), by use
of the same antibodies. Hematopoietic stem cells in total white
blood cell populations, which may be difficult to purify or
isolate, may be transduced in the mixed populations by use of
immobilized CD34 antibodies.
[0084] The cell surface binding molecules of the invention may
target and bind any moiety found on the surface of the cell to be
transduced. Preferably, the moieties are found as part of
receptors, markers, or other proteinaceous or non-proteinaceous
factors on the cell surface. The moieties include epitopes
recognized by the cell surface binding molecule. These epitopes
include those comprising a polypeptide sequence, a carbohydrate, a
lipid, a nucleic acid, an ion and combinations thereof.
[0085] Examples of cell surface binding molecules include an
antibody or an antigen binding fragment thereof and a ligand or
binding domain for a cell surface receptor. The cell surface
binding molecule may itself be a polypeptide, a nucleic acid, a
carbohydrate, a lipid, or an ion. Preferably, the molecule is an
antibody or a fragment thereof, such as a F.sub.ab or F.sub.v
fragment. More preferably, the molecule is not used in a soluble
form but is rather immobilized on a solid medium, such a bead, with
which the cells to be transduced may be cultured, or the surface of
a tissue culture dish, bag or plate, upon which the cells to be
transduced may be cultured. In a preferred embodiment for the
transduction of CD4+ or CD8+ cells, monoclonal antibodies that
recognize CD3 and/or CD28 may be used in a cell culture bag in the
presence of a viral vector.
[0086] The present invention includes compositions comprising a
cell surface binding molecule for use as part of the disclosed
methods. An exemplary composition comprises the molecule and a
viral vector to be transduced, optionally in the presence of the
cells to be transduced. The viral vectors may be derived from any
source, but are preferably retroviral vectors. More preferably,
they are lentiviral vectors. A particularly preferred lentiviral
vector is one derived from a Human Immunodeficiency Virus (HIV),
most preferably HIV-1, HIV-2, or chimeric combinations thereof. Of
course different viral vectors may be simultaneously transduced
into the same cell by use of the present methods. For example, one
vector can be a replication deficient or conditionally replicating
retroviral vector while a second vector can be a packaging
construct that permits the first vector to be replicated/packaged
and propagated. When various viral accessory proteins are to be
encoded by a viral vector, they may be present in any one of the
vectors being transduced into the cell. Alternatively, the viral
accessory proteins may be present in the transduction process via
their presence in the viral particles used for transduction. Such
viral particles may have an effective amount of the accessory
proteins co-packaged to result in an increase in transduction
efficiency. In a preferred embodiment, the viral vector does not
encode one or more of the accessory proteins.
[0087] A viral vector for use in the transduction methods of the
invention can also comprise and express one or more nucleic acid
sequences under the control of a promoter. In one embodiment of the
invention, a nucleic acid sequence encodes a gene product that,
upon expression, would alleviate or correct a genetic deficiency in
the cell to be transduced. In another embodiment, the nucleic acid
sequence encodes or constitutes a genetic antiviral agent that can
prevent or treat viral infection. By "genetic antiviral agent", it
is meant any substance that is encoded or constituted by genetic
material. Examples of such agents are provided in U.S. Pat. No.
5,885,806. They include agents that function by inhibiting viral
proteins, such as reverse transcriptase or proteases; competing
with viral factors for binding or target sites; or targeting viral
targets directly for degradation, such as in the case of ribozymes
and antisense constructs. Other examples of genetic antiviral
agents include antisense, RNA decoys, transdominant mutants,
interferons, toxins, nucleic acids that modulate or modify RNA
splicing, immunogens, and ribozymes, such as "hammerhead" and
external guide sequence (EGS) mediated forms thereof.
[0088] Alternatively, a viral vector can encode a marker for
transduced cells. In the examples presented in the figures and
below, green fluorescent protein (GFP) is the marker encoded by the
viral vector transduced into CD4+ cells. Other markers include
those listed above. Detection of GFP may serve to identify the
number of functionally transduced cells, which were not only
transduced with the vector, but were also able to functionally
express GFP to levels that could be detected by FACS analysis. It
should be noted that the detection may not represent the actual
number of transduced cells since some cells may have been
transduced with the vector but express GFP at levels that are below
the limits used in FACS detection.
[0089] An alternative approach to detecting transfection efficiency
is with the polymerase chain reaction (PCR). For example, TaqMan
PCR can be used to determine the actual number of copies of stably
integrated viral vector in a transduced cell.
[0090] The cells to be transduced may be exposed to contact with
the viral vector either before, after or simultaneously with
contact with the cell surface binding molecule. Thus the cells can
be first exposed to the vector for a period of time followed by
introduction of the cell surface binding molecule. Such cells may
be newly isolated or prepared primary cells that have not been
intentionally stimulated to enter the cell cycle. Alternatively,
the cells can be first exposed to the cell surface binding molecule
for a period of time followed by contact with the viral vector.
After contact with the vector, excess vector is preferably not
removed and the cells cultured under conditions conducive to cell
growth and/or proliferation. Such conditions may be in the presence
of the cell surface binding molecule or other
stimulatory/activating factors, such as cytokines and lymphokines
in the case of T cells. Alternatively, excess vector may be removed
after contact with the cell and before further culturing.
[0091] Another embodiment of the invention is to culture the cells
in the presence of both viral vector and cell surface binding
molecule simultaneously. Such cells are preferably not previously
stimulated. After a period of time, the cells are cultured under
growth or proliferation inducing conditions such as the continued
presence of the cell surface binding molecule or other
stimulatory/activating factors. Alternatively, excess vector may be
removed before further culturing.
[0092] In any of the above combinations of viral vector and cell
surface binding molecule administration, incubation with the vector
can be optionally repeated at least once. Contact with the vector
can also be repeated more than once, such as twice, thrice, four
times, or more.
[0093] Incubation of the cells to be transduced with the viral
vector may be for different lengths of time, depending on the
conditions and materials used. Factors that influence the
incubation time include the cell, vector and MOI (multiplicity of
infection) used, the molecule(s) and amounts used to bind the cell
surface, whether and how said molecule(s) are immobilized, and the
level of transduction efficiency desired. In a preferred embodiment
of the invention, the cells are T lymphocytes, the vector HIV
based, the MOI is about 20, the cell surface binding molecules are
CD3 and CD28 antibodies immobilized on beads, and the resultant
efficiency at least 93%. As would be evident to the skilled person
in the art, some of the above factors are directly correlated while
others are inversely correlated. For example, a decrease in the MOI
will likely decrease the level of efficiency while efficiency can
likely be maintained if an increased amount of cell surface binding
molecules is used.
[0094] The length of incubation viral vector and the cells to be
transformed is preferably for 24 hours and optionally repeated once
for lymphocytes and up to four times for hematopoietic stem cells.
Similarly, and in embodiments where the cells are incubated with
the cell surface binding molecule before introduction of the viral
vector, the incubation may be for about 12 hours to about 96 hours.
Preferably, incubation with a cell surface binding molecule occurs
simultaneously with contact of the cells with the viral vector.
Under such circumstances, the cell surface binding molecules may be
left in contact with the cells when the vector is introduced.
Alternatively, excess cell surface binding molecules may be first
removed from the culture before introduction of the vector to the
cells.
[0095] After contact with the vector, the cells are cultured under
conditions conducive to their growth or proliferation. Preferably,
the conditions are continued culturing in the presence of the cell
surface binding molecules. Alternatively, the cells are initially
cultured with the cell surface binding molecule followed by
substitution with media containing another factor conducive to cell
growth, such as interleukin-2. Yet another embodiment would be to
remove both the excess cell surface binding molecule and the excess
vector followed by culturing in the presence of a factor conducive
to growth or proliferation as well as enhancing further vector
transduction. Such factors include mitogens such as
phytohemaglutinin (PHA) and cytokines, growth factors, activators,
cell surface receptors, cell surface molecules, soluble factors, or
combinations thereof, as well as active fragments of such
molecules, alone or in combination with another protein or factor,
or combinations thereof.
[0096] Examples of additional factors include epidermal growth
factor (EGF), transforming growth factor alpha (TGF-alpha),
angiotensin, transforming growth factor beta (TGF-beta), GDF, bone
morphogenic protein (BMP), fibroblast growth factor (FGF acidic and
basic), vascular endothelial growth factor (VEGF), PIGF, human
growth hormone (HGH), bovine growth hormone (BGH), heregulins,
amphiregulin, Ach receptor inducing activity (ARIA), RANTES
(regulated on activation, normal T expressed and secreted),
angiogenins, hepatocyte growth factor, tumor necrosis factor beta
(TNF-beta), tumor necrosis factor alpha (TNF-alpha), angiopoietins
1 or 2, insulin, insulin growth factors I or II (IGF-I or IGF-2),
ephrins, leptins, interleukins 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, or 15 (IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, or IL-15), G-CSF
(granulocyte colony stimulating factor), GM-CSF
(granulocyte-macrophage colony stimulating factor), M-CSF
(macrophage colony stimulating factor), LIF (leukemia inhibitory
factor), angiostatin, oncostatin, erythropoietin (EPO), interferon
alpha (including subtypes), interferons beta, gamma, and omega,
chemokines, macrophage inflammatory protein-1 alpha or beta (MIP-1
alpha or beta), monocyte chemotactic protein-1 or -2 (MCP-1 or 2),
GRO beta, MIF (macrophage migration inhibitory factor), MGSA
(melanoma growth stimulatory activity), alpha inhibin HGF, PD-ECGF,
bFGF, lymphotoxin, Mullerian inhibiting substance, FAS ligand,
osteogenic protein, pleiotrophin/midkine, ciliary neurotrophic
factor, androgen induced growth factor, autocrine motility factor,
hedgehog protein, estrogen, progesterone, androgen, glucocorticoid
receptor, RAR/RXR, thyroid receptor, TRAP/CD40, EDF (erythroid
differentiating factor), Fic (growth factor inducible chemokine),
IL-1 RA, SDF, NGR or RGD ligand, NGF, thymosine-alpha1, OSM,
chemokine receptors, stem cell factor (SCF), or combinations
thereof. As evident to one skilled in the art, the choice of
culture conditions will depend on knowledge in the art concerning
the cells transduced as well as the subsequent intended use of the
cells. For example, the combination of IL-3, IL-6 and stem cell
factor would not be a choice for transduced cells that are to be
used in human transplantation. Similarly, the choice of culture
conditions would preferably not be to the detriment of cell
viability or transduction efficiency.
[0097] Preferably, the post transduction incubation is for a period
of about four hours, or for about one to about seven to ten days.
More preferably from about 16 to about 20 hours or for about four,
about five or about six days. About fourteen days of
post-transduction incubation is also contemplated.
[0098] The efficiency of transduction observed with the present
invention is from about 75-100%. Preferably, the efficiency is at
least about 75 to 90%. More preferred embodiments of the invention
are where transduction efficiency is at least about 90 to 95%. The
most preferred embodiments have transduction efficiencies of at
least 91, 92, 93, 94, 95, 96, 97, 98, 99 and 100%.
[0099] In addition to the above, the transduced cells may be used
in research or for treatment of disease conditions in living
subjects. Particularly preferred as part of the invention are
therapeutic uses for the transduced cells to produce gene products
of interest or for direct introduction into a living organism as
part of gene therapy. For example, and as exemplified below,
primary T cells can be isolated and transduced with a viral vector.
Successful transduction is indicated by the production or
overproduction of a gene product encoded by the vector or
generation of a phenotype conferred by the vector. As such, primary
T cells can be first transduced with a vector containing, and
capable of expressing, desirable or useful nucleic acid sequences,
and then returned to an in vivo environment such as a living
subject. Preferably, the living subject is an individual infected
with, or at risk of being infected with HIV-1.
[0100] In another embodiment, the T cells are transduced with genes
or nucleic acids capable of conditionally killing the T cell upon
introduction into a host organism. This has applications in
allogenic bone marrow transplantation to prevent graft versus host
disease by killing T cells with a pro-drug approach.
[0101] Alternatively, the primary cells can be deficient in a gene
product, and the deficiency correctable by the transduced viral
vector. Such cells would be reintroduced into the living subject
after transduction with the vector.
[0102] Thus, both in vitro and ex vivo applications of the
invention are contemplated. For transfers into a living subject,
the transduced cells are preferably in a biologically acceptable
solution or pharmaceutically acceptable formulation. Such a
transfer may be made intravenously, intraperitoneally or by other
injection and non-injection methods known in the art. The dosages
to be administered will vary depending on a variety of factors, but
may be readily determined by the skilled practitioner. There are
numerous applications of the present invention, with known or well
designed payloads in the viral vector, where the benefits conferred
by the transduced genetic material will outweigh any risk of
negative effects.
[0103] Initially, the total number of transduced cells transferred
would be from about 10.sup.4 to about 10.sup.10. As such, 10.sup.5,
10.sup.6, 10.sup.7, 10.sup.8, or 10.sup.9 cells may be used. The
actual numbers will vary depending on the cells being transduced.
Multiple transfers, if required, of transduced cells are a
preferable embodiment. Furthermore, conditioning of the host prior
to the transfer of transduced cells, if required, is a preferable
embodiment. Conditioning regimens are known in the art; an example
is the regimen(s) for bone marrow transplantation.
[0104] Having now generally described the invention, the same will
be more readily understood through reference to the following
examples which are provided by way of illustration, and are not
intended to be limiting of the present invention, unless
specified.
EXAMPLE I
Preparation of Primary CD4+ T Cells
[0105] CD4+T cells were isolated from peripheral blood using
standard protocols with slight modification. More specifically,
contaminating monocytes were depleted by attachment. Non adherent
cells were placed in the presence of magnetic beads coated with
anti-CD4 antibodies for positive selection of CD4+ cells. The
magnetic beads were removed and CD4+ cells isolated.
[0106] The highly purified CD4+ cells were confirmed to be greater
than 90% by flow cytometry.
EXAMPLE II
Transduction of Primary CD4+ T cells with Variations in Time of
Contact with a Cell Surface Binding Molecule
[0107] Transduction Before Cell Surface Binding
[0108] Primary CD4+ cells (about 500,000) were cultured with
pN2cGFP at a MOI of 20 for 24 hours followed by addition of
.alpha.CD3 and .alpha.CD28 coated beads to the culture for an
additional seven days. FIG. 1 contains a map of pN2cGFP.
[0109] Transduction After Cell Surface Binding
[0110] Primary CD4+ cells (about 500,000) were cultured for 24
hours with .alpha.CD3 and .alpha.CD28 coated beads for 24 hours
followed by introduction of pN2cGFP at a MOI of 20 to the culture
for an additional 24 hours. The cells were washed to remove excess
vector followed by incubation in vector free media containing the
beads for an additional seven days.
[0111] Simultaneous Transduction and Cell Surface Binding
[0112] Primary CD4+ cells (about 500,000) were cultured with
pN2cGFP at a MOI of 20 for 24 hours in the presence of .alpha.CD3
and .alpha.CD28 coated beads. The cells were washed to remove
excess vector followed by incubation in vector free media
containing the beads for an additional seven days.
[0113] Optional Protocol Substitutions
[0114] Other viral vectors may be substituted for pN2cGFP.
Additionally, the transduction may be repeated for a total of two
times prior to removal of excess vector. Moreover, the .alpha.CD3
and .alpha.CD28 coated beads may be substituted by interleukin-2
(10 ng/ml) and PHA-P (3 mg/ml) after transduction and removal of
excess vector. After seven days, the media is replace with PHA-P
free media containing interleukin-2 (10 ng/ml) and the incubation
continued for an additional seven days.
[0115] Alternatively, after seven days of post-transduction
incubation with .alpha.CD3 and .alpha.CD28 coated beads, the cells
are washed and incubation continued in the presence of
interleukin-2 (10 ng/ml).
EXAMPLE III
[0116] Post-transduction analysis Post-transduction and seven or 14
days after incubation, the cells were analyzed by flow cytometry
for CD4+ and/or green fluorescent protein (GFP).
[0117] A comparison of the above three transduction protocols is
shown in FIG. 2. Contact with bead immobilized CD3 and CD28
antibodies after transduction with pN2cGFP at an MOI of 20 resulted
in about 91% efficiency. Contact with beads before transduction
resulted in about 89% efficiency, and simultaneous bead contact and
transduction resulted in about 80% efficiency. In this experiment,
the CD4+ T cells were selected by adherence monocyte depletion,
CD14 MACS depletion and CD4 MACS enrichment. The antibodies were
immobilized as described below. Contact with the vector was at
37.degree. C. and 5% CO.sub.2. The culture conditions were at
500,000 CD4+ T cells per ml in Yssel's medium supplemented with 2%
human serum albumin. FACS analysis was on day seven post selection.
MF refers to mean fluorescence.
[0118] The results for an experiment after seven days comparing
different stimulation conditions are shown in FIG. 3. CD4+ cells
were treated with either IL-2 and PHA-P or bead immobilized CD3 and
CD28 antibodies for 24 hours followed by one round of transduction
with pN2cGFP at an MOI of 20. In side by side comparisons, the use
of immobilized antibodies resulted in transduction efficiencies of
over 95% each time (indicated by cells positive for both CD4 and
GFP). By comparison, the results with IL-2 and PHA stimulation
resulted on efficiencies of only 70.2 to 84.5%. FACS analysis was
on day seven post selection.
[0119] FIG. 4 shows the results of a similar experiment at 15 days
post selection. Cells were again treated with either IL-2 and PHA-P
or bead immobilized CD3 and CD28 antibodies for 24 hours followed
by one round of transduction with pN2cGFP at an MOI of 20. The
PHA-P and beads were removed on day 7 after transduction, and the
cells were cultured with only IL-2 at 500,000 cells per ml. until
day 15 post selection. Approximately 93% of the cells were positive
for both CD4 and GFP after the use of immobilized antibodies. Only
about 75% of cells treated with IL-2 and PHA remained positive for
both CD4 and GFP. These results indicate that a small fraction of
the cells detected as positive after seven days (FIG. 3) may have
been due to "pseudotransfection."
EXAMPLE IV
[0120] Different Vectors Stably Transduce Cells at High
Efficiencies:
[0121] This example is a comparison of vectors used for
transduction. pN2cGFP contains the entire gag and pol coding
sequence while pN1(cpt)cGFP contains the 4551-5096 partial
(non-coding) pol sequence. As can be seen from the results, shown
in FIG. 5, both vectors show very efficient transduction of primary
CD4 cells after simultaneous stimulation with bead immobilized CD3
and CD28 antibodies and vector at an MOI of 20. FACS analysis was
performed on day 10 post selection.
EXAMPLE V
[0122] Effect of MOI on Transfection Efficiency
[0123] The effect of different MOIs are shown in FIG. 6, where the
use of MOIs from 2 to 20 resulted in transduction efficiencies from
72.7 to 83.8%. Cells were contacted with bead immobilized CD3 and
CD28 antibodies for 24 hours before transduction with pN1(cpt)CGFP
at different MOIs.
EXAMPLE VI
[0124] Transduction of CD34 Positive Cells
[0125] CD34 positive cells were prepared from cord blood and
transduced four times with pN1cptGFP simultaneously in the presence
of FLT-3 ligand, TPO and Kit ligand (100 ng/ml each). The cells
were cultured for five weeks in long term culture (LTC-IC) and then
the cells cultured in methylcellulose for 10 days prior to analysis
(the results are from an elapsed time of over 6 weeks in culture).
The results in FIG. 7 analyze mature CD45 positive cells that
result from the CD34 immature cells. Control cells show no
significant transduction while the vector transduced cells show
over 88% of cells as CD45 and GFP positive.
EXAMPLE VII
[0126] Long Term Transduction of CD34 Positive Cells
[0127] CD34 positive cells were transduced with pN1(cpt)GFP as
described above and transplanted to the bone marrow of partially
irradiated SCID mice. After eight weeks, cells were isolated and
analyzed for CD45 bearing mature human cells and GFP expression by
FACS. The results are shown in FIG. 7, panels A to D.
[0128] Panel A shows the results with a control mouse transplanted
with human cells not transduced with vector.
[0129] Panel B shows the results with a mouse transplanted with
cells transduced with cells transduced with pN1(cpt)GFP vector at a
MOI of 50 for 4 sequential days in the presence of 100 ng/ml of
FLT-3 ligand, TPO and Kit ligand. This mouse shows a striking 96.3%
transduction efficiency of transduced human cells (CD45 positive
cells) 8 weeks after transduction. The level of human cell
engraftment in this mouse was 11.1%, consistent with previously
reported results.
[0130] Panels C and D show the results with two other mice treated
as in panel B. The results confirm reproducibility of high
efficiency transduction with 87.8% and 89.6% of CD45 positive cells
also being GFP positive.
[0131] The average efficiency is 91.2%, which reflects long term
stable transduction.
EXAMPLE VIII
[0132] Immobilization of Cell Surface Binding Molecules
[0133] This example describes the direct linkage of CD3 (B-B 11)
antibodies and CD28 (B-T3) antibodies to epoxy dynal beads for use
in the examples below.
[0134] 1. Prepare 0.1 borate solution by dissolving 0.618 g. boric
acid in 95 ml of tissue culture grade water. Mix well and adjust pH
to 9.5 using highest quality NaOH. Bring final volume to 100 ml and
sterilize via a 0.2 .mu.m filter. Seal container and store at
4.degree. C.
[0135] 2. Add antibody to above borate solution at a concentration
of 150 .mu.g/ml. For both B-B 11 and B-T3 antibodies, add 75 .mu.g
of each per ml of borate solution. Bring volume to 1 ml total.
Borate concentration should not be below 0.05 M after adding
antibody. For each 1 ml of borate/antibody solution, add
4.times.10.sup.8 Epoxy beads.
[0136] 3. Incubate 24 hours at 37.degree. C. on rotating wheel.
[0137] 4. Wash beads three times for 10 min. each at 22.degree. C.
with bead wash media: phosphate buffered saline without calcium and
magnesium, 3% human serum albumin, 5 mM EDTA, and 0.1 sodium
azide.
[0138] 5. Wash beads once for 30 min at 22.degree. C.
[0139] 6. Wash overnight at 4.degree. C.
[0140] 7. Replace with fresh bead wash media, resuspend beads to
2.times.10.sup.8 beads/ml. IgG coated beads are stable for at least
6 months at 4.degree. C.
EXAMPLE IX
[0141] Transduction of Dendritic Cells
[0142] Monocytes from peripheral blood were isolated and then
transduced for three consecutive days at an MOI of 50 with pN2cGFP
using two simultaneous cytokine conditions: GM-CSF (800 units/ml),
IL-4 (500 units/ml) and TNF-alpha (100 units/ml) or GM-CSF (500
units/ml) and interferon-alpha (800 units/ml). FIG. 9, panel A,
shows the results seven days post transduction where the first
cytokine condition resulted in 90.2% efficiency. Cells transduced
with vector under the second cytokine conditions show a 92.9%
efficiency after seven days (panel B). CD86 is only one possible
marker for dendritic cells, and it should be noted that CD86
negative cells can also be dendritic cells.
REFERENCES
[0143] Barry, S. C. et al. (2000) "Lentiviral and murine retroviral
transduction of T cells for expression of human CD40 ligand" Human
Gene Therapy 11:323-332.
[0144] Costello, E. et al. (2000) "Gene transfer into stimulated
and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors"
Gene Therapy 7:596-604.
[0145] Douglas, J. et al. (1999) "Efficient transduction of human
lymphocytes and CD34+ cells via human immunodeficiency virus-based
gene transfer vectors" Human Gene Therapy 10:935-945.
[0146] Follenzi, A. et al. (2000) "Gene transfer by lentiviral
vectors is limited by nuclear translocation and rescued by HIV-1
pol sequences" Nature Genetics 25:217-222.
[0147] Han, W. et al. (2000) "A soluble form of human Delta-like-1
inhibits differentiation of hematopoietic progenitor cells" Blood
95:1616-1625.
[0148] Haas, D. L., et al. (2000) "Critical factors influencing
stable transduction of human CD34+ cells with HIV-1-derived
lentiviral vectors" Molecular Therapy 2:71-80.
[0149] Hooijberg E. et al. (2000) "NFAT-controlled expression of
GFP permits visualization and isolation of antigen-stimulated
primary human T cells" Blood 96:459466.
[0150] Kishimoto, T. (ed). Leucocyte Typing VI: White Cell
Differentiation Antigens: Proceedings of the Sixth International
Workshop and Conference Held in Kobe, Japan, 10-14 November 1996.
Garland Publishing, New York, 1998.
[0151] Klebba, C. et al. (2000) "Retrovirally expressed anti-HIV
ribozymes confer a selective survival advantage on CD4+ T cells in
vitro" Gene Therapy 7:408-416.
[0152] Koc, O. N., et al. (1999) "Transfer of drug resistance genes
into hematopoietic progenitors" Chapter 11, Gene Therapy of Cancer,
Academic Press, San Diego, pp. 177-195.
[0153] Movassagh, M. et al. (2000) "Retrovirus-mediated gene
transfer into T cells: 95% transduction efficiency without further
in vitro selection" Human Gene Therapy 11:1189-1200.
[0154] Onodera, M. et al. (1998) "Successful peripheral
T-lymphocyte-directed gene transfer for a patient with severe
combined immune deficiency caused by adenosine deaminase
deficiency" Blood 91:30-36.
[0155] St. Croix, B., et al. (2000) "Genes expressed in human tumor
endothelium" Science 289:1197-1202.
[0156] Unutmaz, D. et al. (1999) "Cytokine signals are sufficient
for HIV-1 infection of resting human T lymphocytes" J. Exp. Med.
11: 1735-1746.
[0157] Zennou, V., et al. (2000) "HIV-1 genome Nuclear import is
mediated by a central DNA flap" Cell 101:173-185.
[0158] All references cited herein are hereby incorporated by
reference in their entireties, whether previously specifically
incorporated or not.
[0159] Having now fully described this invention, it will be
appreciated by those skilled in the art that the same can be
performed within a wide range of equivalent parameters,
concentrations, and conditions without departing from the spirit
and scope of the invention and without undue experimentation.
[0160] While this invention has been described in connection with
specific embodiments thereof, it will be understood that it is
capable of further modifications. This application is intended to
cover any variations, uses, or adaptations of the invention
following, in general, the principles of the invention and
including such departures from the present disclosure as come
within known or customary practice within the art to which the
invention pertains and as may be applied to the essential features
herein before set forth as follows in the scope of the appended
claims.
[0161] Hereinabove and in the claims below, use of the terms "a" or
"an" is not limited to defining the singular state. Instead, use of
the terms encompasses the plural state. For example the term "an
antibody" is not limited to the singular state of one single
antibody molecule, but rather encompasses the presence of a
plurality of antibody molecules so long as they are identical
copies of the antibody being referred to. Similarly, "a viral
vector" is not limited to one single viral vector molecule or one
single viral particle.
* * * * *
References